You would like to read
- dunnhumby in spotlight at largest-ever Virtual Machine Learning Summit
- Tredence launches ML Works, machine learning ops platform to accelerate AI innovation and value realization
- StackRoute announces Data Science Foundation Program and Advanced Post Graduate Program in Data Science and Machine Learning to meet the industry requirement
- Cycle Strike: Event concluded in the presence of Deputy Commissioner of Baramulla
- Tredence included in Now Tech - Customer Analytics Service Providers, Q2 2021
Hyderabad (Telangana) [India], August 24 (ANI/PRNewswire): (https://www.excelra.com) Excelra launches a re-envisioned version of (https://www.gostardb.com) GOSTAR, its structure-activity relationship application, with an innovative set of new features to accelerate the drug discovery cycle.
Today, Excelra, a global data science and data analytics company, unveiled an improved version of GOSTAR, its flagship chemistry insights engine. The enhancements offer advanced search, analysis, and visualization capabilities enabling drug discovery scientists to accelerate the hit identification and lead optimization process.
"Drug discovery researchers need to ensure that they are getting the broadest possible view of structure-activity data while being able to readily drill down to the most meaningful data points. The new GOSTAR version has been re-envisioned based on extensive user feedback to provide researchers with an intuitive interface that reduces time to market for new drugs. It incorporates analytical capabilities, eliminating the need to use multiple tools to assess compounds while also providing insights directly within the application. The result is a rapid and more confident decision-making process," said Norman Azoulay, Director, Scientific Products.
GOSTAR's industry-leading capabilities include:
* Advanced Search: Discover insights faster with dynamic, flexible, and interactive search capabilities
* SAR View: View, sort, and export structures based on activity against targets of interest
* Analytics: Compare compounds and perform Molecular pair, maximum common substructure, and ligand efficiency vs. ligand-lipophilicity efficiency analyses
All data in GOSTAR, which now includes over 8 million compounds, along with bioactivity data, is subjected to a three-tiered, QMS-ISO certified quality control process. The standardization and normalization of all data provide additional clarity while ensuring it is directly and readily comparable.
"Excelra aims to transform life science data into actionable insights for our R & D clients that help them to innovate and accelerate their drug discovery. The enhancements made to GOSTAR will improve the ability to make meaningful predictions and lead to more promising pipelines," said Anandbir Singh Brar, CEO, Excelra.
GOSTAR is available as an application for users to seek, find, and discover compounds. In addition, it is offered via APIs and as a downloadable dataset to power in-house libraries and machine learning models.
For more information about GOSTAR, visit (https://www.gostardb.com)
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
